Moderate

Erythrocytosis / polycythaemia work-up

polycythaemia w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A raised haematocrit/haemoglobin requires distinguishing true erythrocytosis from apparent (plasma-contracted) polycythaemia, and primary (polycythaemia vera) from secondary causes, because management and thrombotic risk differ markedly.

Red flags

  • Thrombosis (arterial or venous, including splanchnic)
  • Hyperviscosity symptoms (visual disturbance, headache, confusion)
  • Haematocrit markedly elevated
  • Splanchnic vein thrombosis (consider occult PV)
  • Erythromelalgia with vascular events

Assessment

Differential diagnosis

  • Polycythaemia vera (JAK2)
  • Secondary (hypoxia, smoking, EPO-secreting tumour, high altitude)
  • Apparent/relative polycythaemia (dehydration, obesity, diuretics)
  • Congenital high-affinity haemoglobin
  • Testosterone/anabolic steroid use

Investigations

  • Confirm persistently raised haematocrit/haemoglobin
  • JAK2 V617F mutation (and exon 12 if negative but suspicious)
  • Serum erythropoietin (low in PV, high in secondary)
  • Oxygen saturation / carboxyhaemoglobin (smoking)
  • Ferritin, renal and liver function, abdominal imaging for EPO-secreting tumour
  • Bone marrow if PV suspected

Management

  • Confirm the result is sustained and not spurious
  • Assess for symptoms of hyperviscosity and thrombosis risk
  • Distinguish apparent from true erythrocytosis (red cell mass rarely needed now)
  • Test JAK2 V617F - positivity with other criteria supports polycythaemia vera
  • Measure erythropoietin: low suggests PV, raised/normal points to secondary causes
  • Screen for secondary drivers: hypoxia, smoking, sleep apnoea, renal/hepatic tumours, exogenous androgens
  • Diagnose polycythaemia vera using haemoglobin/haematocrit, JAK2 and marrow criteria
  • Manage PV with venesection to target haematocrit <0.45, aspirin, and cytoreduction if high risk
  • Treat secondary causes by addressing the underlying stimulus
  • Give cardiovascular risk reduction and arrange appropriate follow-up

Drugs & doses

Aspirin 75-100 mg PO once daily (polycythaemia vera)
Therapeutic venesection to keep haematocrit <0.45 (PV)
Hydroxycarbamide 15-20 mg/kg/day PO (high-risk PV cytoreduction)
Ruxolitinib for hydroxycarbamide-resistant/intolerant PV

Disposition

Haematology outpatient work-up; PV managed long term by haematology; treat secondary causes in the relevant speciality.

Complications & pitfalls

  • Arterial and venous thrombosis
  • Haemorrhage
  • Transformation of PV to myelofibrosis or acute leukaemia
  • Hyperviscosity
  • Pruritus (PV)

Exam pearls

  • A low erythropoietin with JAK2 positivity strongly suggests polycythaemia vera
  • Target haematocrit below 0.45 to reduce thrombosis in PV
  • Smoking and sleep apnoea are common secondary causes
  • Unexplained splanchnic thrombosis should prompt JAK2 testing
  • Apparent polycythaemia (contracted plasma volume) needs no cytoreduction

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.